Navigation Links
Intellikine Completes $51 Million Financing
Date:7/8/2009

LA JOLLA, Calif., July 8 /PRNewswire/ -- Intellikine, Inc., a leader in the development of innovative, small molecule drugs for the treatment of cancer, inflammation and autoimmune diseases, announced today that it has raised $51 million in preferred stock financing. Novartis Bioventures Ltd. led the financing in which additional new investors U.S. Venture Partners, Biogen Idec and FinTech Global Capital participated. Markus Goebel, M.D., Ph.D., Managing Director of the Novartis Venture Funds, will join the company's board of directors.

The investment includes a $28.5 million first closing. In addition, the company can access up to another $22.5 million, subject to the performance of certain milestones, which, if triggered, will bring the total amount raised in this round to $51 million. This latest financing comes less than two years after the company was formed with an initial investment of $12.5 million from founding investors Abingworth, CMEA Capital and Sofinnova Ventures, all of whom participated in this latest financing.

Intellikine is developing a portfolio of isoform-selective inhibitors of the phosphatidyinositol-3-kinase (PI3K) pathway for the treatment of cancer, inflammation and autoimmune diseases. The company has discovered multiple classes of proprietary compounds that are potent, selective and druglike inhibitors of PI3K isoforms. The company's most advanced compound, INK128, a selective TORC1/2 inhibitor, has demonstrated efficacy in multiple models of cancer and is expected to enter Phase I clinical studies within twelve months.

"We are delighted to have generated such excitement among both new and existing investors," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Intellikine. "This financing gives us the resources necessary to advance our pipeline of PI3K/mTOR inhibitors into clinical development as well as significant flexibility to build strategic partner
'/>"/>

SOURCE Intellikine, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
2. Verenium Completes Amendment to 8% Senior Convertible Notes
3. Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
4. Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial
5. Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait
6. EFT BioTech Holdings, Inc.s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait
7. Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
8. Cordex Completes Production of ATPace(TM) Clinical Trial Material
9. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
10. Brooks Instrument Completes Acquisition of Celerity's Instrumentation Division
11. Sinovac Completes Construction of H1N1 Virus Seed Bank
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Florida (PRWEB) , ... September 02, 2015 , ... ... been treated and managed with the use of special anti-vascular endothelial growth factor ... in many more patients, currently does not have a scientific protocol for the ...
(Date:9/2/2015)... 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "Biomarkers ... offering. This report follows the broad ... can be objectively measured and evaluated as an ... well as pharmacological responses to a therapeutic intervention. ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cqsxmg/gene_therapy ... report "Gene Therapy - Technologies, Markets and Companies" ... gene therapy are difficult to estimate as there is ... marketed in China since 2004. ... The estimates are based on epidemiology of diseases to ...
(Date:9/2/2015)... 2015 Research ... the addition of Jain PharmaBiotech,s new report ... to their offering. The ... fluorescence in situ hybridization (FISH), comparative genomic ... includes application of nanobiotechnology, microarrays, real-time polymerase ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3
... Divine Skin (OTC Bulletin Board: DSKX ) has ... its diverse consumer goods business and accelerate development through its ... RECORD 2010 REVENUE.  Divine Skin started the ... $1.9 million or 55 percent over 2009. ...
...  MedTRACK, an Informa business unit, and the world,s ... unveiled a premier partnering tool for the J.P. ... attending the conference find licensing, investment and acquisition ... Filter companies can quickly identify like-minded suitors in ...
... a privately held biotechnology company that develops next ... receive a milestone payment from Boehringer Ingelheim.  The ... agreement executed in October 2010 to discover, develop ... Re-Targeting (DART) platform.  The amount of the milestone ...
Cached Biology Technology:Another Successful Year at Divine Skin 2Another Successful Year at Divine Skin 3MedTRACK Unveils Partnering Tool for J.P. Morgan Healthcare Conference 2MacroGenics Receives Milestone Payment as Part of Its Global DARTâ„¢ Alliance with Boehringer Ingelheim 2
(Date:9/2/2015)... , September 2, 2015 ... security purpose implied in a system which uses ... voice, signature, iris, vein, DNA and finger print. ... forced to develop such system which provides high ... password, PIN, Patterns and tokens are vulnerable to ...
(Date:9/1/2015)... MOUNTAIN VIEW, Calif. , Sept. 1, 2015 ... interaction with travelers during airport passenger screening. This ... which the passenger screening process will become unintrusive. ... and pre-clearance based on voluntary background investigations will ... analysis from Frost & Sullivan, Global Airport ...
(Date:8/31/2015)... 31, 2015 Growing need for ... government digitization projects to drive India ... TechSci Research report, " India Biometrics Market Forecast & Opportunities, ... is projected to grow at a CAGR of over 35% ... on account of extensive use of biometric technology in the ...
Breaking Biology News(10 mins):Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3
... Virginia Key, FL March 14, 2011 -- The University ... proud to announce that Dr. Peter Mumby is the 2011 ... honors. Mumby, a British marine ecologist and professor at Australia,s ... Award. His goal is to understand the benefits and limitations ...
... common parasitic infection can vary greatly from person to person, ... three strains of the cat-borne parasite Toxoplasma gondii ... invades. Past research suggests that the parasite, estimated to ... psychotic symptoms and schizophrenia in genetically predisposed people. The ...
... premier plant biology journals published by the American Society of ... The Plant Cell -- completed their migration to HighWire ... HighWire, the online hosting platform for more than 1,000 scholarly ... a standards-based hosting solution that is putting ASPB,s journals at ...
Cached Biology News:Peter Mumby to receive prestigious 2011 Rosenstiel Award from the University of Miami 2Toxoplasmosis: The strain explains severity of infection 2ASPB journals migrate to new Web platform 2
... sets a new standard for high performance ... new design in instrumentation, this easy-to-use benchtop ... The BD FACSAria instrument is the first ... flow cell. This new flow cell ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Mouse monoclonal antibody raised against a full length recombinant LDB3. NCBI Entrez Gene ID = LDB3...
Biology Products: